Lineage Cell Therapeutics, Inc. Increase (Decrease) in Deferred Revenue
Lineage Cell Therapeutics, Inc. (LCTX) reported Increase (Decrease) in Deferred Revenue of -$1.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-06
- Lineage Cell Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was -$698.00K.
- Lineage Cell Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was -$995.00K.
- Lineage Cell Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was -$518.00K.
- Lineage Cell Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was -$1.78M.
- Lineage Cell Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2025 was -$6.11M.
- Lineage Cell Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2024 was -$7.68M.
- Lineage Cell Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2023 was -$7.64M.
- Lineage Cell Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2022 was -$13.35M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 3 month as first filed | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 6 month as first filed | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 9 month as first filed | Increase (Decrease) in Deferred Revenue 12 month | Increase (Decrease) in Deferred Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$698.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.69M 10-Q · filed 2026-08-06 | -$2.21M derived: sum of 3 quarters · filed 2026-08-06 | -$3.99M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$995.00K 10-Q · filed 2026-05-12 | -$1.51M derived: sum of 2 quarters · filed 2026-05-12 | -$3.29M derived: sum of 3 quarters · filed 2026-05-12 | -$5.83M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | -$518.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$2.30M derived: sum of 2 quarters · filed 2026-03-05 | -$4.83M derived: sum of 3 quarters · filed 2026-08-06 | -$6.11M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | -$1.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$4.31M derived: sum of 2 quarters · filed 2026-08-06 | -$5.59M 10-Q · filed 2025-11-06 | -$8.07M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$2.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.81M 10-Q · filed 2026-08-06 | -$6.29M derived: sum of 3 quarters · filed 2026-08-06 | -$9.68M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$1.28M 10-Q · filed 2026-05-12 | -$3.76M derived: sum of 2 quarters · filed 2026-05-12 | -$7.14M derived: sum of 3 quarters · filed 2026-05-12 | -$7.74M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | -$2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$5.86M derived: sum of 2 quarters · filed 2026-03-05 | -$6.46M derived: sum of 3 quarters · filed 2026-03-05 | -$7.68M 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | -$3.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.98M derived: sum of 2 quarters · filed 2025-11-06 | -$5.20M 10-Q · filed 2025-11-06 | -$6.81M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | -$598.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$1.82M 10-Q · filed 2025-08-12 | -$3.42M derived: sum of 3 quarters · filed 2025-08-12 | -$4.38M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | -$1.22M 10-Q · filed 2025-05-13 | -$2.83M derived: sum of 2 quarters · filed 2025-05-13 | -$3.78M derived: sum of 3 quarters · filed 2025-05-13 | -$6.74M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | -$1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$2.56M derived: sum of 2 quarters · filed 2025-03-10 | -$5.52M derived: sum of 3 quarters · filed 2025-03-10 | -$7.64M 10-K · filed 2025-03-10 | ||||
| 2023-09-30 | -$956.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$3.92M derived: sum of 2 quarters · filed 2024-11-14 | -$6.04M 10-Q · filed 2024-11-14 | -$7.80M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | -$2.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$5.08M 10-Q · filed 2024-08-08 | -$6.84M derived: sum of 3 quarters · filed 2024-08-08 | |||||
| 2023-03-31 | -$2.12M 10-Q · filed 2024-05-09 | -$3.88M derived: sum of 2 quarters · filed 2024-05-09 | ||||||
| 2022-12-31 | -$1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$13.35M 10-K · filed 2024-03-07 | ||||||
| 2022-09-30 | -$11.59M 10-Q · filed 2023-11-09 | |||||||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-09 | |||||||
| 2016-12-31 | $265.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$1.36M derived: sum of 2 quarters · filed 2017-03-16 | $117.00K derived: sum of 3 quarters · filed 2017-08-09 | $132.00K 10-K · filed 2017-03-16 | ||||
| 2016-09-30 | -$1.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$148.00K derived: sum of 2 quarters · filed 2017-08-09 | -$133.00K 10-Q · filed 2016-11-04 | $569.00K derived: sum of 4 quarters · filed 2017-08-09 | ||||
| 2016-06-30 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $1.50M 10-Q · filed 2017-08-09 | -$59.00K 10-Q · filed 2016-08-09 | $2.20M derived: sum of 3 quarters · filed 2017-08-09 | $2.12M derived: sum of 4 quarters · filed 2017-08-09 | |||
| 2016-03-31 | $15.00K 10-Q · filed 2016-05-10 | $717.00K derived: sum of 2 quarters · filed 2017-03-16 | $636.00K derived: sum of 3 quarters · filed 2017-03-16 | $817.00K derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-12-31 | $702.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $621.00K derived: sum of 2 quarters · filed 2017-03-16 | $802.00K derived: sum of 3 quarters · filed 2017-03-16 | $772.00K 10-K · filed 2017-03-16 | ||||
| 2015-09-30 | -$81.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $100.00K derived: sum of 2 quarters · filed 2016-11-04 | $70.00K 10-Q · filed 2016-11-04 | $102.00K derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-06-30 | $181.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $151.00K 10-Q · filed 2016-08-09 | $183.00K derived: sum of 3 quarters · filed 2017-03-16 | $90.00K derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-03-31 | -$30.00K 10-Q · filed 2016-05-10 | -$29.81K 10-Q · filed 2015-05-08 | $2.00K derived: sum of 2 quarters · filed 2017-03-16 | -$91.00K derived: sum of 3 quarters · filed 2017-03-16 | $1.40K derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | $32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$61.00K derived: sum of 2 quarters · filed 2017-03-16 | $31.40K derived: sum of 3 quarters · filed 2017-03-16 | -$26.00K 10-K · filed 2017-03-16 | -$26.34K 10-K · filed 2015-03-11 | |||
| 2014-09-30 | -$93.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$598.00 derived: sum of 2 quarters · filed 2015-11-09 | -$58.00K 10-Q · filed 2015-11-09 | -$57.42K 10-Q · filed 2014-11-07 | -$72.54K derived: sum of 4 quarters · filed 2016-03-15 | |||
| 2014-06-30 | $92.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $35.00K 10-Q · filed 2015-08-10 | $35.35K 10-Q · filed 2014-08-11 | $20.46K derived: sum of 3 quarters · filed 2016-03-15 | -$46.38K derived: sum of 4 quarters · filed 2016-03-15 | |||
| 2014-03-31 | -$57.40K 10-Q · filed 2015-05-08 | -$71.94K derived: sum of 2 quarters · filed 2016-03-15 | -$138.78K derived: sum of 3 quarters · filed 2016-03-15 | |||||
| 2013-12-31 | -$14.54K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$81.38K derived: sum of 2 quarters · filed 2016-03-15 | -$19.00K 10-K · filed 2016-03-15 | -$19.24K 10-K · filed 2014-03-17 | ||||
| 2013-09-30 | -$66.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$4.46K 10-Q · filed 2014-11-07 | -$50.54K 10-Q · filed 2013-11-12 | |||||
| 2013-06-30 | $62.38K 10-Q · filed 2014-08-11 | $62.28K 10-Q · filed 2013-08-09 | ||||||
| 2012-12-31 | $320.16K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-11 | $199.09K derived: sum of 2 quarters · filed 2015-03-11 | $212.10K 10-K · filed 2015-03-11 | |||||
| 2012-09-30 | -$121.07K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | -$108.06K 10-Q · filed 2013-11-12 | ||||||
| 2012-06-30 | $13.02K 10-Q · filed 2013-08-09 | $0.00 10-Q · filed 2012-08-09 | ||||||
| 2011-12-31 | $23.09K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $22.87K derived: sum of 2 quarters · filed 2014-03-17 | $22.53K derived: sum of 3 quarters · filed 2014-03-17 | $0.00 10-K · filed 2014-03-17 | ||||
| 2011-09-30 | -$219.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | -$558.00 derived: sum of 2 quarters · filed 2012-08-09 | -$23.09K 10-Q · filed 2011-11-08 | -$23.91K derived: sum of 4 quarters · filed 2013-03-18 | ||||
| 2011-06-30 | -$339.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | -$22.87K 10-Q · filed 2012-08-09 | -$23.69K derived: sum of 3 quarters · filed 2013-03-18 | $13.81K derived: sum of 4 quarters · filed 2013-03-18 | ||||
| 2011-03-31 | -$22.53K 10-Q · filed 2012-05-10 | -$23.35K derived: sum of 2 quarters · filed 2013-03-18 | $14.15K derived: sum of 3 quarters · filed 2013-03-18 | |||||
| 2010-12-31 | -$818.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $36.68K derived: sum of 2 quarters · filed 2013-03-18 | $36.68K 10-K · filed 2013-03-18 | |||||
| 2010-09-30 | $37.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | $37.50K 10-Q · filed 2011-11-08 | ||||||
| 2010-06-30 | $0.00 10-Q · filed 2011-08-09 | |||||||
| 2009-12-31 | $75.00K 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |